Comparison of W_max (A), the changes in V_E (B), and W_VT (C) among the three oxygen conditions. by Kazufumi Hisamoto (21416905)

Mean frequency of the cultural trait <i>T</i> in the population when <i>T</i> decreases fertility. by Laurel Fogarty (143721)

Developmental delay of <i>rpS13/+</i> animals is not due to a decrease in ribosome numbers or reduced translation rates. by Lisa Patricia Deliu (13570709)

CC-1⁺ immunostained cell numbers decrease by 2 days after TBI and return to control levels by 5 weeks. by Krista A. Dent (709531)

“…Panels show contralateral (Contra) and ipsilateral (Ipsi) external capsule (EC) at (A,B) 2 days (2d), (C,D) 2 weeks (2w) and (E,F) 5 weeks (5w) (G) In the external capsule numbers of CC-1⁺ oligodendrocytes were decreased by 2d after injury, remained decreased at 2 weeks and returned to normal levels by 5 weeks. …”

Increased anxiety- and depression-like behavior in W/W^v mice. by Sachiko Chikahisa (417256)

“…<p>(A) Anxiety-like behavior in an elevated plus maze in WT and W/W^v mice at baseline. Total distance (left panel), time spent in open arms (center panel) and number of instances of entry into open arms (right panel) was decreased in W/W^v mice compared to that of WT mice. …”

Baseline sleep/wake characterizations of WT and W/W^v mice. by Sachiko Chikahisa (417256)

“…Amount of REM (bottom) was slightly decreased in W/W^v mice during the light phase (L; ZT0-12) but was not during the dark phase (D; ZT12-24). …”

Effect of 5-HTR blockade on cost-based motivation. by Yukiko Hori (299784)

Anandamide decreases exploratory behavior in the large open field. by Adriaan W. Bruijnzeel (2605954)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantification of <i>ATP5B</i> mRNA and β-F1-ATPase protein expression shows decreased protein translation in obesity. by Lee Tran (2106961)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects: